Abstract
Androgen deprivation therapy (ADT) which remains the first line of therapy for patients with metastatic prostate cancer (PCa) has been associated with metabolic abnormalities and significant risk of cardiovascular disease (CVD) (1). Based on observational studies and two meta-analyses, ADT increases the risk for cardiovascular events but results from randomized clinical trials and relevant subsequent meta-analyses did not confirm those conclusions (1). This literature discrepancy in cardiovascular outcomes in patients on ADT may be associated with lack of evaluation of different types of ADT including gonadotropin-releasing hormone (GnRH) agonists, orchiectomy or anti-androgens, absence of comparison to age-matched patients without PCa, and not assessing pre-existing CVD as a confounding factor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
